Can Fite Biopharma Ltd
canfite.comWhat Do They Do?
Develops orally taken small-molecule drug candidates for cancer, liver and inflammatory diseases, and erectile dysfunction, for pharmaceutical partners.
20-F for FY2025, filed Mar 26, 2026We are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the…View ↗
Our product candidates, CF101, CF102 and CF602, are being developed to treat oncological and inflammatory diseases, as well as erectile…View ↗
Commercialize our product candidates throughout-licensing arrangements. We have entered into several out-licensing arrangements with…View ↗
How Do They Make Money?
Pharmaceutical partners pay upfront fees tied to development work, milestone payments when agreed development or sales goals are reached, and royalties when licensed products sell.
20-F for FY2025, filed Mar 26, 2026The Company generates revenues from supply and distribution agreements. The consideration under these agreements comprises of upfront fees…View ↗
Revenue from supply and distribution agreements with customers are recognized over time as the Company satisfies the performance…View ↗
The Company’s contracts generally include three contract obligations: (i) performing the research and development services through…View ↗
The Company’s contracts also include development milestones payments and future sales-based royalties.View ↗
Sales based royalties are recognized only when the subsequent sale occurs. As of December 31, 2025, the Company has not yet received the…View ↗
$405K
-
20-F for FY2025, filed Mar 26, 2026
$405K ↗
Who Are Their Customers?
Pharmaceutical partners obtain regional distribution rights for drug candidates through licensing agreements. Partners may handle development, regulatory approval, manufacturing, marketing and sales.
20-F for FY2025, filed Mar 26, 2026Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or…View ↗
Namodenoson for the treatment of (i) liver cancer and MASH to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver…View ↗
Commercialize our product candidates throughout-licensing arrangements. We have entered into several out-licensing arrangements with…View ↗
20-F for FY2025, filed Mar 26, 2026
Year ended December 31, 2025 2024 2023 Cipher Pharmaceuticals (Canada) 11 % 7 % 11 % Chong Kun Dang Pharmaceuticals Corp. (South Korea) 19…View ↗
Do Revenues Turn Into Profits?
No. It lost $9.8M in FY2025.
20-F for FY2025, filed Mar 26, 2026
−$10MView ↗
20-F for FY2025, filed Mar 26, 2026
−$9.8MView ↗
20-F for FY2025, filed Mar 26, 2026
−$9MView ↗
How Are They Changing?
Shrinking. Revenue fell 53% in 4 years, from $853K in FY2021 to $405K in FY2025, about 17% a year.
Who Do They Compete With?
Competes with Amgen, J&J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB, Takeda, Alumis, Bayer, Exelixis, Merck, Roche, Eisai, AstraZeneca, BeOne Oncology, Madrigal Pharmaceuticals, Novo Nordisk, and GSK
20-F for FY2025, filed Mar 26, 2026On the other hand, other drugs on the market, new drugs under development (including drugs that are in more advanced stages of development…View ↗
Loading...
